Quoin Pharmaceuticals Ltd
NASDAQ:QNRX
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.48
5.4
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one QNRX stock under the Base Case scenario is 3.399 USD. Compared to the current market price of 0.669 USD, Quoin Pharmaceuticals Ltd is Undervalued by 80%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Quoin Pharmaceuticals Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for QNRX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Quoin Pharmaceuticals Ltd
Balance Sheet Decomposition
Quoin Pharmaceuticals Ltd
Current Assets | 13.2m |
Cash & Short-Term Investments | 12.6m |
Other Current Assets | 650.7k |
Non-Current Assets | 833.3k |
Intangibles | 533.3k |
Other Non-Current Assets | 300k |
Current Liabilities | 4m |
Accounts Payable | 819.7k |
Accrued Liabilities | 2.5m |
Short-Term Debt | 600k |
Non-Current Liabilities | 2.6m |
Long-Term Debt | 2.6m |
Earnings Waterfall
Quoin Pharmaceuticals Ltd
Revenue
|
0
USD
|
Operating Expenses
|
-8.9m
USD
|
Operating Income
|
-8.9m
USD
|
Other Expenses
|
661.9k
USD
|
Net Income
|
-8.3m
USD
|
Free Cash Flow Analysis
Quoin Pharmaceuticals Ltd
USD | |
Free Cash Flow | USD |
The company has commenced 2024 on a strong note, optimistic about building on the positive initial data for its lead asset targeting Netherton syndrome, a rare genetic disorder. With the age eligibility for clinical studies now lowered to 14, the company expects a diverse study population and plans to enroll as many eligible pediatric patients as possible. Despite the challenges, the balance sheet remains robust after a successful capital raise and a strategic equity line of credit (ELOC) arrangement, placing the company in a robust position to complete clinical testing. Top-line results from the blinded study are anticipated early in 2025, with further data from the open-label study expected to be released throughout the year.
What is Earnings Call?
QNRX Profitability Score
Profitability Due Diligence
Quoin Pharmaceuticals Ltd's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Quoin Pharmaceuticals Ltd's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
QNRX Solvency Score
Solvency Due Diligence
Quoin Pharmaceuticals Ltd's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Score
Quoin Pharmaceuticals Ltd's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
QNRX Price Targets Summary
Quoin Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for QNRX is 4.76 USD with a low forecast of 2.02 USD and a high forecast of 10.5 USD.
Dividends
Current shareholder yield for QNRX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
QNRX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Quoin Pharmaceuticals Ltd. is a specialty pharmaceutical company engaged in the development of therapeutic products for the treatment of rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
Officers
The intrinsic value of one QNRX stock under the Base Case scenario is 3.399 USD.
Compared to the current market price of 0.669 USD, Quoin Pharmaceuticals Ltd is Undervalued by 80%.